Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688315 | 0.89 | SLC6A4 (0.42) | HTR1ASLC6A4KCNA3HTR1BHTR2A | |
| SCHEMBL7834298 | 0.83 | HTR1A (0.41) | HTR1ASLC6A4KCNA3HTR1BEGLN1 | |
| SCHEMBL4180176 | 0.83 | HTR1B (0.54) | HTR1ASLC6A4KCNA3HTR1BEGLN1 | |
| SCHEMBL4313222 | 0.83 | HTR1A (0.41) | HTR1ASLC6A4KCNA3HTR1BEGLN1 | |
| SCHEMBL3789397 | 0.83 | MCHR1 (0.46) | HTR1ASLC6A4HTR1B | |
| SCHEMBL3795511 | 0.81 | MCHR1 (0.48) | HTR1ASLC6A4HTR1B | |
| SCHEMBL3796715 | 0.79 | ADORA3 (0.49) | — | |
| SCHEMBL7928500 | 0.78 | NCF1 (0.40) | HTR1ASLC6A4LMNA | |
| SCHEMBL23544480 | 0.77 | GAA (0.45) | HTR1ASLC6A4LMNANPC1 | |
| SCHEMBL11811685 | 0.75 | HTR1A (0.38) | HTR1ASLC6A4KCNA3HTR1BEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | HTR1A 307/4885SLC6A4 1029/4885KCNA3 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.